{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:06:20Z","timestamp":1790701580565,"version":"4.1.0"},"reference-count":15,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T00:00:00Z","timestamp":1604275200000},"content-version":"unspecified","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Faculty of Medicine Ramathibodi Hospital","award":["CF_63001"],"award-info":[{"award-number":["CF_63001"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2020,10,21]]},"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>To characterise patients with refractory SLE receiving rituximab biosimilar (CT-P10) and to explore short-term efficacy and safety associated with rituximab biosimilar use.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We retrospectively analysed data from the medical records of patients with refractory SLE who received CT-P10 in Ramathibodi Hospital, Mahidol University, Thailand. Baseline characteristics, disease activity (modified Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)), response to treatment at 6 months after CT-P10 and infection over 6 months were recorded.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Thirty-two patients with SLE received CT-P10 from April 2018 to June 2019. Of these, 29 (90.6%) were female and the mean\u00b1SD age was 36.8\u00b115.2 years. The median (IQR) disease duration was 9.5 (1.3\u201313.0) years. All patients received glucocorticoid treatment and used 1.7\u00b10.1 immunosuppressive agents at baseline, excluding antimalarial drugs. Baseline Systemic Lupus International Collaborating Clinics Damage Index score was 0.5 (0.0\u20131.0). Overall response, which was defined as a reduction in the modified SLEDAI score of \u22654, was achieved in 25.0% of patients at 6 months. The modified SLEDAI score reduced from 4 (1.3\u20138.0) at baseline to 1 (0.0\u20135.8) at 6 months (p=0.005). Response by active organ involvement was 71.8%. Serious infection occurred in four patients (12.5%), resulting in one death. The median time of onset of infection after CT-P10 infusion was 35.5 (17.0\u201372.5) days.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Rituximab biosimilar is associated with improvement in active organ involvement in patients with refractory SLE. Infection occurred early after rituximab biosimilar infusion.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/lupus-2020-000442","type":"journal-article","created":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T16:05:58Z","timestamp":1604333158000},"page":"e000442","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and safety of rituximab biosimilar in refractory lupus"],"prefix":"10.1136","volume":"7","author":[{"given":"Nantakarn","family":"Pongtarakulpanit","sequence":"first","affiliation":[{"name":"Division of Allergy, Immunology and Rheumatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prapaporn","family":"Pisitkun","sequence":"additional","affiliation":[{"name":"Division of Allergy, Immunology and Rheumatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7948-1748","authenticated-orcid":false,"given":"Pintip","family":"Ngamjanyaporn","sequence":"additional","affiliation":[{"name":"Division of Allergy, Immunology and Rheumatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,11,2]]},"reference":[{"key":"2025091512381986000_7.1.e000442.1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-017-0707-z"},{"key":"2025091512381986000_7.1.e000442.2","doi-asserted-by":"publisher","DOI":"10.1002\/art.27233"},{"key":"2025091512381986000_7.1.e000442.3","doi-asserted-by":"publisher","DOI":"10.1002\/art.34359"},{"key":"2025091512381986000_7.1.e000442.4","doi-asserted-by":"publisher","DOI":"10.1177\/0961203309106174"},{"key":"2025091512381986000_7.1.e000442.5","doi-asserted-by":"publisher","DOI":"10.1002\/art.27541"},{"key":"2025091512381986000_7.1.e000442.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2011.10.009"},{"key":"2025091512381986000_7.1.e000442.7","doi-asserted-by":"publisher","DOI":"10.1177\/0961203313503912"},{"key":"2025091512381986000_7.1.e000442.8","first-page":"449","article-title":"Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian multicentre registry","volume":"33","author":"Iaccarino","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"2025091512381986000_7.1.e000442.9","doi-asserted-by":"crossref","first-page":"118","DOI":"10.5152\/eurjrheum.2018.17096","article-title":"Outcomes of rituximab therapy in refractory lupus: a meta-analysis","volume":"5","author":"Alshaiki","year":"2018","journal-title":"Eur J Rheumatol"},{"key":"2025091512381986000_7.1.e000442.10","doi-asserted-by":"publisher","DOI":"10.1177\/0961203317749047"},{"key":"2025091512381986000_7.1.e000442.11","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex395"},{"key":"2025091512381986000_7.1.e000442.12","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2017.1359537"},{"key":"2025091512381986000_7.1.e000442.13","first-page":"1934","article-title":"The systemic lupus activity Measure-revised, the Mexican systemic lupus erythematosus disease activity index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus","volume":"31","author":"Uribe","year":"2004","journal-title":"J Rheumatol"},{"key":"2025091512381986000_7.1.e000442.14","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100724"},{"key":"2025091512381986000_7.1.e000442.15","doi-asserted-by":"publisher","DOI":"10.1186\/s42358-019-0055-y"}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2020-000442","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T19:38:30Z","timestamp":1757965110000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2020-000442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,11,2]]},"published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1136\/lupus-2020-000442"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2020-000442","relation":{},"ISSN":["2053-8790"],"issn-type":[{"value":"2053-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11]]}}}